BR112012004237A2 - método para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10) - Google Patents

método para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)

Info

Publication number
BR112012004237A2
BR112012004237A2 BR112012004237A BR112012004237A BR112012004237A2 BR 112012004237 A2 BR112012004237 A2 BR 112012004237A2 BR 112012004237 A BR112012004237 A BR 112012004237A BR 112012004237 A BR112012004237 A BR 112012004237A BR 112012004237 A2 BR112012004237 A2 BR 112012004237A2
Authority
BR
Brazil
Prior art keywords
alterator
epimetabolic
coenzyme
sarcoma
treating
Prior art date
Application number
BR112012004237A
Other languages
English (en)
Other versions
BR112012004237A8 (pt
Inventor
John Patrick Mccook
Niven Rajin Narain
Rangaprasad Sarangarajan
Original Assignee
Cytotech Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytotech Labs Llc filed Critical Cytotech Labs Llc
Publication of BR112012004237A2 publication Critical patent/BR112012004237A2/pt
Publication of BR112012004237A8 publication Critical patent/BR112012004237A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
BR112012004237A 2009-08-25 2010-08-25 métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10) BR112012004237A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23684509P 2009-08-25 2009-08-25
PCT/US2010/046711 WO2011031503A2 (en) 2009-08-25 2010-08-25 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)

Publications (2)

Publication Number Publication Date
BR112012004237A2 true BR112012004237A2 (pt) 2016-04-05
BR112012004237A8 BR112012004237A8 (pt) 2016-10-04

Family

ID=43730801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004237A BR112012004237A8 (pt) 2009-08-25 2010-08-25 métodos para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)

Country Status (15)

Country Link
US (2) US20110064747A1 (pt)
EP (1) EP2470169A4 (pt)
JP (2) JP6159085B2 (pt)
KR (1) KR101572463B1 (pt)
CN (2) CN108245497A (pt)
AU (2) AU2010292532A1 (pt)
BR (1) BR112012004237A8 (pt)
CA (1) CA2772068C (pt)
CR (1) CR20120120A (pt)
EA (1) EA201270325A1 (pt)
IL (1) IL218306B (pt)
IN (1) IN2012DN01911A (pt)
MX (1) MX2012002208A (pt)
SG (2) SG10201405069QA (pt)
WO (1) WO2011031503A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2430455A4 (en) 2009-05-11 2013-09-04 Berg Pharma Llc METHOD FOR THE DIAGNOSIS OF METABOLISM DISORDERS WITH EPIMETABOLIC SHIFTERS, MULTI-DIMENSIONAL INTRA CELLULAR MOLECULES OR AMBIENT INFLUENCES
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
CN110151591A (zh) 2012-10-09 2019-08-23 宝洁公司 鉴定协同化妆品组合的方法
EP2906946A1 (en) 2012-10-09 2015-08-19 The Procter & Gamble Company Method of identifying or evaluating beneficial actives and compositions containing the same
US9144538B2 (en) 2013-02-08 2015-09-29 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating the signs of photoaged skin
US9138393B2 (en) 2013-02-08 2015-09-22 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for improving the appearance of aging skin
CN105338973A (zh) * 2013-04-08 2016-02-17 博格有限责任公司 使用辅酶q10联合疗法治疗癌症
SG11201601583TA (en) 2013-09-04 2016-04-28 Berg Llc Methods of treatment of cancer by continuous infusion of coenzyme q10
CA2952615A1 (en) 2014-06-17 2015-12-23 Stealth Biotherapeutics Corp Methods of identifying and monitoring mitochondrial dysfunction using monocyte screening
CN107001451A (zh) * 2014-07-07 2017-08-01 阿勒根公司 检测组织样品中裂解的snap25的方法
CN105044360A (zh) * 2015-07-22 2015-11-11 浙江大学医学院附属邵逸夫医院 Rbp4作为结直肠癌血清标记物的应用及诊断试剂盒
CN106053813A (zh) * 2016-06-25 2016-10-26 林森 一种检测鼻咽癌pdk1表达量的免疫组化试剂盒及其应用
CN106947010B (zh) * 2017-04-06 2018-12-11 哈尔滨工业大学 一种利用光引发raft聚合原位诱导自组装制备蛋白质基纳米粒子的方法
CA3063916A1 (en) 2017-05-17 2018-11-22 Berg Llc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
CN107226862A (zh) * 2017-05-27 2017-10-03 南京川博生物技术有限公司 特异性人ews‑fli1融合蛋白抗体的制备方法及在制备尤文肉瘤诊断抗体试剂的应用
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ, インコーポレイテッド 機械学習を使用するデータ圧縮および通信
EP4301393A1 (en) * 2021-03-05 2024-01-10 University of Central Florida Research Foundation, Inc. Chaperonin-containing tcp-1 inhibitors for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702148C (en) * 1999-01-06 2014-03-04 Genenews Inc. Method of profiling gene expression in a human subject having an infectious disease
WO2003087404A1 (en) * 2002-04-17 2003-10-23 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
JP2006345701A (ja) * 2003-07-01 2006-12-28 Taisho Pharmaceut Co Ltd タキサン類応答性の判別方法
US20060035981A1 (en) * 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
JP5247031B2 (ja) * 2004-01-22 2013-07-24 ユニバーシティー・オブ・マイアミ 局所用コエンザイムq10製剤
AU2005245572B9 (en) * 2004-05-14 2009-01-29 Ludwig Institute For Cancer Research Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib
EP1894012A2 (en) * 2005-05-18 2008-03-05 Novartis AG Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2343276T3 (es) * 2005-09-02 2010-07-27 Toray Industries, Inc. Kit y metodo para la deteccion del cancer urotelial.
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US8211634B2 (en) 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8030013B2 (en) * 2006-04-14 2011-10-04 Mount Sinai School Of Medicine Methods and compositions for the diagnosis for early hepatocellular carcinoma
US8148090B2 (en) * 2007-10-18 2012-04-03 Medical Proteoscope Co., Ltd. Method for prediction of postoperative prognosis and diagnosis kit

Also Published As

Publication number Publication date
CN108245497A (zh) 2018-07-06
IL218306A0 (en) 2012-04-30
SG10201405069QA (en) 2014-10-30
CN102548549A (zh) 2012-07-04
WO2011031503A2 (en) 2011-03-17
US20110064747A1 (en) 2011-03-17
WO2011031503A3 (en) 2011-07-21
IL218306B (en) 2018-05-31
KR20120050495A (ko) 2012-05-18
BR112012004237A8 (pt) 2016-10-04
JP6159085B2 (ja) 2017-07-05
KR101572463B1 (ko) 2015-11-27
EP2470169A4 (en) 2013-03-13
AU2016277749A1 (en) 2017-02-02
JP2016136938A (ja) 2016-08-04
CR20120120A (es) 2012-07-04
IN2012DN01911A (pt) 2015-07-24
US20130266557A1 (en) 2013-10-10
EA201270325A1 (ru) 2012-11-30
MX2012002208A (es) 2012-06-12
SG178547A1 (en) 2012-03-29
JP2013503175A (ja) 2013-01-31
CA2772068C (en) 2017-03-21
AU2010292532A1 (en) 2012-04-05
EP2470169A2 (en) 2012-07-04
CA2772068A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
BR112012004237A2 (pt) método para tratamento de um sarcoma usando um alterador epimetabólico (coenzima q10)
BRPI1010827A2 (pt) métodos para tratamento de doença usando um transferidor epimetabólico (coenzima q10)
BRPI1008672A2 (pt) método para tratar um furo de poço.
BRPI1013219A2 (pt) método para o alvejamento-branqueamento enzimático têxtil
BR112012006989A2 (pt) método para usar um dispositivo de entretenimento
PL3339052T3 (pl) Sposób dekorowania powierzchni
BR112012002746A2 (pt) método para produção de copolímero
GB201112645D0 (en) An inkless printing method
PL2776634T3 (pl) Sposób montażu wieży morskiej
BRPI0923266A2 (pt) metodo para recuperacao avancada de petroleo
GB201208147D0 (en) Edge-exclusion spalling method for inproving substrate reusability
IL213320A0 (en) Method for geolocating an object by multitelemetry
BRPI0922490A2 (pt) Método para produção de beta-santaleno
EP2236467A4 (en) PROCESS FOR SLUDGE DRYING
BR112012012238A2 (pt) artigo abrasivo; e método para a formação de um artigo abrasivo
BRPI0911077A2 (pt) método para tratamento de biomassa
EP2422916A4 (en) LASER PROCESSING PROCEDURES
IL232700A0 (en) Inspection method and facility, and lithography facility accordingly
EP2650276A4 (en) PROCESS FOR PRODUCTION OF -FLUOROALCOOL
SG11201503318PA (en) Method for microcontact embossing
BR112013024004A2 (pt) método e aparelho para detectar a posição de uma transportadora.
EP2788701B8 (de) Verfahren zum trocknen von schlamm
BR112013028192A2 (pt) dispositivo de geração de hidrogênio, e, método para utilizar um dispositivo de geração de hidrogênio
EP2497914A4 (en) CAM DEVICE
EP2791829A4 (en) METHOD OF ACQUIRING CONTEXT BASED ON RULES

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: BERG PHARMA LLC (US)

B25D Requested change of name of applicant approved

Owner name: BERG LLC (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.